March 20 - 22, 2023
BIO-EUROPE SPRING 2023
Latest Press Releases
December 8, 2022
OMEICOS Therapeutics Announces Expansion of OMT-28 Clinical Development Program into Primary Mitochondrial Diseases
September 3, 2019
OMEICOS Therapeutics Appoints Dr Simon Russell as Chief Business Officer
April 29, 2019
OMEICOS Therapeutics Announces First-Dosing in Phase 2 Clinical Study Evaluating its Lead Program OMT-28 in Patients with Persistent Atrial Fibrillation
February 11, 2019
OMEICOS Therapeutics Strengthens Board of Directors with the Appointment of Christian Schetter
November 2, 2018
OMEICOS Therapeutics Closes €17m Series C Financing to Advance Lead Candidate OMT-28 Towards Pivotal Trials in Atrial Fibrillation
July 17, 2018
OMEICOS Therapeutics Announces Compelling First-in-Human Data on Lead Compound OMT-28 and Prepares Phase 2 Trial in Atrial Fibrillation
April 27, 2018
Alexander Gebauer Joins Executive Board of OMEICOS Therapeutics and Named CEO and Chairman of OMEICOS Ophthalmics
November 13, 2017
OMEICOS Announces Formation of Inaugural Clinical Advisory Board
October 4, 2017
OMEICOS Secures Extension of Series B Financing Round to Expand its Technology into Ophthalmology
June 7, 2017
OMEICOS Secures Continued BMBF Support with New €1.7M Research Grant to Advance its Novel Approach to Treat Cardiovascular Diseases
March 1, 2017
OMEICOS Announces First Closing of €8.3 Million Series B Financing Round and the Initiation of Phase 1 Clinical Trial
November 2, 2015
OMEICOS Receives BMBF Research Grant to Advance its Novel Approach to Treat Atrial Fibrillation
